La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Sutro Biopharma Gestione
Gestione criteri di controllo 2/4
Sutro Biopharma's Il CEO è Bill Newell, nominato in Jan2009, e ha un mandato di 15.58 anni. la retribuzione annua totale è $ 2.13M, composta da 32.2% di stipendio e 67.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.41% delle azioni della società, per un valore di $ 1.42M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 5.2 anni.
Informazioni chiave
Bill Newell
Amministratore delegato
US$2.1m
Compenso totale
| Percentuale dello stipendio del CEO | 32.2% |
| Mandato del CEO | 15.7yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 1.6yrs |
| Durata media del Consiglio di amministrazione | 5.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sep 23There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Aug 24
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Aug 22Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | US$2m | US$687k | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$3m | US$663k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$6m | US$625k | -US$106m |
| Sep 30 2021 | n/a | n/a | -US$127m |
| Jun 30 2021 | n/a | n/a | -US$79m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$554k | -US$32m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$497k | -US$56m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$9m | US$482k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$30m |
| Dec 31 2017 | US$703k | US$468k | -US$20m |
Compensazione vs Mercato: La retribuzione totale di Bill ($USD 2.13M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.46M ).
Compensazione vs guadagni: La retribuzione di Bill è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Bill Newell (66 yo)
15.7yrs
Mandato
US$2,129,980
Compensazione
Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 15.7yrs | US$2.13m | 0.41% $ 1.2m | |
| Chief Scientific Officer | less than a year | US$1.63m | 0.029% $ 84.4k | |
| Chief Medical Officer | 1.6yrs | US$2.34m | 0.030% $ 85.3k | |
| President & COO | less than a year | US$1.43m | 0.066% $ 189.9k | |
| Founder | no data | Nessun dato | Nessun dato | |
| CFO & Secretary | 11.7yrs | US$2.08m | 0.13% $ 373.6k | |
| Chief Technical Operations Officer | 1.3yrs | Nessun dato | 0.039% $ 111.0k | |
| General Counsel | 3.5yrs | Nessun dato | Nessun dato | |
| Chief People & Communications Officer | 16.7yrs | US$1.30m | 0.10% $ 291.7k | |
| Chief Business Development Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President & Controller | no data | Nessun dato | Nessun dato |
1.6yrs
Durata media
62yo
Età media
Gestione esperta: Il team dirigenziale di STRO non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 15.7yrs | US$2.13m | 0.41% $ 1.2m | |
| Independent Chair of the Board | 5.3yrs | US$173.11k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$138.11k | 0% $ 0 | |
| Independent Director | 10.6yrs | US$138.11k | 0.069% $ 197.1k | |
| Independent Director | 15.1yrs | US$140.11k | 0.027% $ 78.6k | |
| Member of Scientific Advisory Board | 1.7yrs | US$1.53m | 0.12% $ 351.3k | |
| Chair of the Scientific Advisory Board | 4.3yrs | Nessun dato | Nessun dato | |
| Independent Director | 6.2yrs | US$133.11k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$152.11k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Clinical Advisory Board | 4.3yrs | Nessun dato | Nessun dato | |
| Independent Director | 2.8yrs | US$150.28k | 0% $ 0 |
5.3yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di STRO sono considerati esperti (durata media dell'incarico 5.2 anni).